Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma
Files
Publication date
2015-11
Authors
Adams, Hugo J A
Nievelstein, Rutger A J
Kwee, Thomas C.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Bone marrow involvement in lymphoma may have prognostic and therapeutic consequences. Bone marrow biopsy (BMB) is the established method for the evaluation of the bone marrow. 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) plays an important role in lymphoma staging, but its value in the assessment of the bone marrow and whether it can replace BMB is still a topic of debate and investigation. The purpose of this scientific communication is to provide an evidence-based overview about the opportunities and limitations of BMB and FDG-PET in the evaluation of the bone marrow in patients with lymphoma. This article first reviews the basic properties, opportunities and limitations of BMB and bone marrow FDG-PET, and then focuses on the clinical utility of BMB and bone marrow FDG-PET in three major lymphoma subtypes including Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.
Keywords
Bone marrow, Diffuse large B-cell lymphoma, FDG-PET, Follicular lymphoma, Hodgkin lymphoma, Hematology, Oncology, Journal Article, Research Support, Non-U.S. Gov't, Review
Citation
Adams, H J A, Nievelstein, R A J & Kwee, T C 2015, 'Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma', Blood Reviews, vol. 29, no. 6, pp. 417-425. https://doi.org/10.1016/j.blre.2015.06.003